Legacy Financial Strategies LLC Cuts Stock Position in AbbVie Inc. $ABBV

Legacy Financial Strategies LLC trimmed its position in AbbVie Inc. (NYSE:ABBV) by 66.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,359 shares of the company’s stock after selling 12,664 shares during the period. Legacy Financial Strategies LLC’s holdings in AbbVie were worth $1,472,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ABBV. MA Private Wealth purchased a new stake in shares of AbbVie in the third quarter valued at about $266,000. Oppenheimer Asset Management Inc. lifted its holdings in shares of AbbVie by 2.6% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 185,944 shares of the company’s stock valued at $43,053,000 after buying an additional 4,730 shares during the period. Tempus Wealth Planning LLC boosted its stake in shares of AbbVie by 13.8% in the third quarter. Tempus Wealth Planning LLC now owns 5,161 shares of the company’s stock valued at $1,195,000 after buying an additional 624 shares in the last quarter. Candriam S.C.A. grew its holdings in AbbVie by 45.1% during the third quarter. Candriam S.C.A. now owns 835,716 shares of the company’s stock worth $193,502,000 after acquiring an additional 259,924 shares during the period. Finally, Beckerman Institutional LLC purchased a new position in AbbVie in the third quarter worth $465,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of research analyst reports. BMO Capital Markets reiterated an “outperform” rating and set a $258.00 target price on shares of AbbVie in a research report on Thursday, January 15th. JPMorgan Chase & Co. increased their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Scotiabank began coverage on shares of AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target for the company. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, Berenberg Bank set a $275.00 target price on AbbVie in a report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Stock Performance

Shares of ABBV stock opened at $223.50 on Monday. The stock has a market capitalization of $395.01 billion, a price-to-earnings ratio of 94.70, a PEG ratio of 0.85 and a beta of 0.35. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company’s 50-day simple moving average is $223.74 and its 200-day simple moving average is $219.84.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period last year, the company earned $2.16 earnings per share. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Morgan Stanley raised its price target to $270 and kept an “overweight” call, signaling institutional analyst conviction that AbbVie has double‑digit upside from current levels. Read More.
• Positive Sentiment: Company forecasts for full‑year 2026 profit came in above estimates, driven by strong sales of newer immunology drugs (Skyrizi, Rinvoq), supporting the case for continued top‑line and earnings growth. Read More.
• Positive Sentiment: Market commentary and some analysts view the post‑earnings pullback as a buying opportunity, pointing to institutional accumulation, durable cash flow, and a strong dividend as anchors for medium‑term returns. Read More.
• Positive Sentiment: New real‑world Rinvoq data from Japan bolsters the drug’s addressable market for ankylosing spondylitis and reinforces growth prospects for AbbVie’s immunology franchise. Read More.
• Neutral Sentiment: Management framed the earnings call around “new growth engines” — Skyrizi/Rinvoq and other launches taking the lead in driving growth, which supports the long‑term story but doesn’t eliminate near‑term volatility. Read More.
• Neutral Sentiment: Q4 results beat on revenue and showed strong margin/earnings leverage, confirming product momentum even as some segments face headwinds. Read More.
• Negative Sentiment: Shares initially gapped down after the print as investors focused on a softer-than‑expected Q1 EPS and revenue outlook despite the quarter’s beats — a classic near‑term reaction to guidance misses. Read More.
• Negative Sentiment: AbbVie set Q1 2026 EPS guidance at $2.97–$3.01 (vs. ~3.11 consensus) and gave revenue guidance below the street, creating short‑term uncertainty about the cadence of 2026 growth. Read More.
• Negative Sentiment: Broader coverage highlighted investor “angst” and a bifurcated reaction — bullish on medium‑term fundamentals but worried about near‑term comps and valuation — keeping volatility elevated. Read More.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.